Last reviewed · How we verify
Rosiglitazone XR
Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.
Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Rosiglitazone XR |
|---|---|
| Also known as | Placebo, Rosiglitazona |
| Sponsor | GlaxoSmithKline |
| Drug class | Thiazolidinedione (PPAR-γ agonist) |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By binding to PPAR-γ in adipose tissue and muscle, rosiglitazone enhances insulin signaling and glucose uptake, reducing hepatic glucose production and improving peripheral insulin sensitivity. This leads to decreased fasting and postprandial blood glucose levels in patients with type 2 diabetes. The XR (extended-release) formulation provides once-daily dosing convenience.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia (when combined with other agents)
- Upper respiratory tract infection
- Headache
- Myalgia
Key clinical trials
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers (PHASE3)
- Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers (PHASE3)
- A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites. (PHASE1)
- PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers (PHASE1)
- Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease (PHASE3)
- Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR) (PHASE1)
- The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosiglitazone XR CI brief — competitive landscape report
- Rosiglitazone XR updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI